Q-omics provides the consensus-scored WDR61 profile across patient tissues and cancer cell-line models. WDR61 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WDR61 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, WDR61 protein abundance shows 20,972 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where WDR61 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR61 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR61 survival associations across molecular data types. WDR61 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR61 RNA expression–survival associations across cancer types. High WDR61 expression shows unfavorable associations in UVM, LGG and STAD, but favorable associations in KIRC, OV and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WDR61 RNA expression.
This table summarizes WDR61 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WDR61. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR61 shows lower tumor expression in THCA, KICH and KIRP and higher tumor expression in LIHC, COAD and CHOL. The THCA box plot shows higher WDR61 RNA expression in normal versus tumor tissue (log2 FC = −0.745, t-test p < 0.001).
This table shows molecular features associated with WDR61 in patient tissues and cancer cell lines. In patient samples, WDR61 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR61 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
